Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 7/20 | 0.62 |
| ▸ | NMBR | P28336 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.59 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSH | P09668 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGAV | P06756 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.56 |
| ▸ | GLP1R | P43220 | 2/20 | 0.55 |
| ▸ | GCGR | P47871 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bombesin SCHEMBL29364598 | 0.97 | GRPR (0.66) | GRPRNMBRCTSLCTSSCTSK | |
| SCHEMBL29565297 | 0.94 | GRPR (0.68) | GRPRNMBRCTSLCTSSCTSK | |
| SCHEMBL30783571 | 0.91 | GRPR (0.65) | GRPRNMBRRXFP1 | |
| Bombesin SCHEMBL29353003 | 0.90 | GRPR (0.70) | GRPRNMBR | |
| Bombesin SCHEMBL29711302 | 0.90 | GRPR (0.76) | GRPRPTH1R | |
| Bombesin SCHEMBL3049338 | 0.90 | GRPR (0.76) | GRPRPTH1R | |
| SCHEMBL31060626 | 0.89 | GRPR (0.58) | GRPRRXFP1PTH1RGLP1R | |
| SCHEMBL30192248 | 0.88 | GRPR (0.71) | GRPRNMBRCTSLCTSSCTSK | |
| SCHEMBL20764459 | 0.87 | GRPR (0.56) | GRPRNMBRCTSLCTSSCTSK | |
| SCHEMBL31694516 | 0.86 | GLP1R (0.63) | PTH1RGLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485191-B2 | Radiopharmaceuticals and methods of use thereof | BOARD OF REGENTS OF THE UNIVERISTY OF NEBRASKA (US) | 2025-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485191-B2 | Radiopharmaceuticals and methods of use thereof | FOLH1, SSTR4, SLC18A2 | GRPR 17/4885NMBR 116/4885CTSL 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.